Clinical trials
Observational Desmoid Tumors trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2013 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2020 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Recruiting | 6 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 4 |
| Istituto Ortopedico Rizzoli | 4 |
| Children's Oncology Group | 3 |
| Abramson Cancer Center at Penn Medicine | 1 |
| Erasmus Medical Center | 1 |
| Mayo Clinic | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Peking University Third Hospital | 1 |
| Technische Universität Dresden | 1 |
| Triemli Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Desmoid Tumors | 19 |
| Chordoma | 2 |
| Colorectal Neoplasms | 2 |
| Desmoplastic Small Round Cell Tumor | 2 |
| Fibroma | 2 |
| Gardner Syndrome | 2 |
| Neoplasms | 2 |
| Sarcoma | 2 |
| Adenomatous Polyposis Coli | 1 |
| Carcinoma in Situ | 1 |
Trials
Showing 51 to 19 of 19. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.